Carisoprodol: risk for addiction and withdrawal
November 12, 2012, 9:26 pm
Carisoprodol: Update on Abuse Potential and Legal Status. Reeves RR et al. Southern Med J 2012 Nov;105:619-623.
Carisoprodol (Soma) is a centrally actingskeletal muscle relaxant that is metabolized to meprobamate, a drug that was a popular sedative before it was supplanted by the benzodiazepines. Both drugs activate GABAA receptors.
The primary manifestation of carisoprodol overdose is CNS depression. Tremor, myoclonus, and muscular rigidity are also seen.
Carisoprodol is associated with addiction and abuse. A withdrawal syndrome — which can occur after stopping even small doses — presents with anxiety, insomnia, irritability, tremors, and hallucinations.
Since January 11, 2012, carisoprodol has been classified as a schedule IV drug by the DEA.
Nothing new in this article, but it is a good review of the addiction potential represented by carisoprodol, and recent regulatory changes.